Outlook Therapeutics has encountered a significant hurdle in its journey towards bringing ONS-5010, also known as LYTENAVA, to the market for treating wet age-related macular degeneration (wet AMD). The U.S. Food and Drug Administration (FDA) recently issued a complete response letter (CRL) regarding the resubmitted biologics license application (BLA) for this innovative therapy. The agency cited that it cannot approve the application in its current form, leaving the company and many stakeholders reflecting on the implications of this decision.
Commitment to Patients
Bob Jahr, the CEO of Outlook Therapeutics, expressed disappointment over the FDA’s decision but reaffirmed the company’s commitment to patients. “Our goal has always been to provide patients with wet AMD and their physicians with a safe, consistent, FDA-approved alternative to compounded Avastin manufactured in the United States,” Jahr stated. This commitment remains unwavering as the company evaluates its next steps.
Data-Driven Challenges
The BLA resubmission for ONS-5010 was backed by robust data from the NORSE clinical trial program. This program included the pivotal NORSE TWO trial, which was well-controlled and designed to provide substantial evidence of safety and efficacy. The trial results, along with data from other studies like NORSE EIGHT, aimed to demonstrate that ONS-5010 could serve as a viable on-label alternative for patients requiring treatment for wet AMD.
However, the FDA’s CRL indicates that the regulatory body may not find the collected data sufficiently compelling to establish the drug’s efficacy and safety. Speculations suggest that issues related to the noninferiority endpoint in the NORSE EIGHT trial could have influenced the FDA’s decision. This adds a layer of complexity to the approval process, highlighting the need for robust clinical evidence.
The Path Forward
Despite the setback, Outlook Therapeutics is actively exploring all available avenues for approval in the United States. The company remains optimistic about the potential of ONS-5010, emphasizing its unique formulation specifically designed for intravitreal use. The ongoing evaluations may include re-assessing the clinical data or even conducting additional trials to address the FDA’s concerns.
International Progress
While the FDA’s decision has created challenges in the U.S. market, Outlook Therapeutics has achieved significant milestones abroad. LYTENAVA has already received marketing authorization in the European Union and the UK for treating wet AMD. It became commercially available in Germany and the UK in June 2025, marking a crucial step in the product’s international reach. This dual-path strategy underscores the company’s commitment to bringing this treatment to patients, regardless of regulatory hurdles in specific regions.
Expert Insights
In light of the FDA’s decision, experts in the field have weighed in on the implications for retina specialists and current treatment practices. Dr. David A. Eichenbaum, a prominent figure in retinal research, noted that the non-approval of ONS-5010 will not significantly alter the established use of off-label bevacizumab. The historical reliance on off-label usage has created entrenched prescribing patterns, and retina specialists are likely to continue utilizing existing treatment options for their patients.
Future Considerations
As Outlook Therapeutics navigates the aftermath of the CRL, questions arise regarding the necessary steps for future submissions. Experts suggest that the company may need to conduct at least one well-designed trial similar to NORSE EIGHT, but with positive outcomes, to gain FDA approval. This would not only bolster the case for ONS-5010 but also influence the broader landscape for ophthalmic formulations of bevacizumab.
Takeaways
- The FDA’s CRL for ONS-5010 highlights the challenges of proving drug efficacy and safety in competitive therapeutic markets.
-
Outlook Therapeutics remains committed to patient care and continues to seek pathways for regulatory approval.
-
The international success of LYTENAVA emphasizes the potential for market expansion despite domestic setbacks.
-
Experts believe that past treatment patterns with off-label bevacizumab will persist, minimizing immediate impacts on clinical practices.
-
Future submissions may require additional trials to meet the FDA’s stringent approval criteria.
In conclusion, while the CRL presents a formidable challenge for Outlook Therapeutics, it also serves as a reminder of the complexity and rigor involved in the drug approval process. The company’s resolve to pursue regulatory pathways and the ongoing support from the medical community could pave the way for future advancements in treating wet AMD. The journey is far from over, and the commitment to patients remains a central tenet of Outlook Therapeutics’ mission.
Read more on ophthalmologytimes.com